Understanding immune deficiency in untreated Chronic Lymphocytic Leukemia patients
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
This study looks at how untreated Chronic Lymphocytic Leukemia affects the immune system and tries to find out why these patients are more likely to get infections.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Trial ID | NCT06475469 on ClinicalTrials.gov |
What this trial studies
This study investigates the immune dysfunction associated with untreated Chronic Lymphocytic Leukemia (CLL) and aims to identify predictive factors for infectious risk in these patients. It involves blood sampling and chest CT scans to assess lymphocyte subpopulations and the prevalence of bronchiectasis. The research focuses on understanding how CLL leads to immunosuppression and increased susceptibility to infections, which are significant complications in these patients. By analyzing these factors, the study seeks to improve patient management and outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are untreated patients over 18 years of age diagnosed with Chronic Lymphocytic Leukemia.
Not a fit: Patients who have previously received treatment for Chronic Lymphocytic Leukemia or are legally protected may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk assessment and management strategies for infections in patients with Chronic Lymphocytic Leukemia.
How similar studies have performed: While the specific approach of this study may be novel, there is existing literature on the immune dysfunction in CLL, suggesting that similar studies have provided valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Untreated CLL patients * Patients \> 18 years of age * Patients agreing to participate to the study * Patients inured under the french social security system Exclusion Criteria: * Previously treated CLL patients * Patients protected by law
Where this trial is running
Reims
- Chu Reims — Reims, France (Recruiting)
Study contacts
- Study coordinator: Anne QUINQUENEL, Pr.
- Email: aquinquenel@chu-reims.fr
- Phone: 03.26.78.74.76
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.